Oxford BioSciences Jonathan Fleming And Chris Kim On Investing in Korea: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
All eyes are on the Korea-Seoul Life Science Fund to see how the collaboration between the Boston-based venture capital firm Oxford Biosciences, Korea’s Hanwha Venture Capital, the Seoul Metropolitan Government and the Korea Institute for Advancement of Technology under the Ministry of Knowledge Economy will evolve.
You may also be interested in...
NEW YORK - Oxford Bioscience Partners has chosen Korea as its first Asian country to invest in via a partnership with Hanwha Venture Capital in Seoul
Recent research advances and relaxation of government restrictions have opened the stem cell field to product possibilities. Companies developing these potentially revolutionary products must also come up with workable business models. In this issue we profile five emerging contenders: Amorcyte, California Stem Cell, Cardio3 BioSciences, CellDesign and Fate Therapeutics.
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.